Beacon Pointe Advisors LLC Sells 425 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Beacon Pointe Advisors LLC lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 19,676 shares of the biopharmaceutical company's stock after selling 425 shares during the period. Beacon Pointe Advisors LLC's holdings in Regeneron Pharmaceuticals were worth $14,015,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Virtu Financial LLC bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $6,364,000. Morse Asset Management Inc boosted its holdings in shares of Regeneron Pharmaceuticals by 0.9% during the 3rd quarter. Morse Asset Management Inc now owns 4,807 shares of the biopharmaceutical company's stock valued at $5,053,000 after buying an additional 43 shares in the last quarter. Anchor Investment Management LLC grew its position in shares of Regeneron Pharmaceuticals by 212.0% in the 3rd quarter. Anchor Investment Management LLC now owns 858 shares of the biopharmaceutical company's stock worth $902,000 after buying an additional 583 shares during the period. Sculati Wealth Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 1.9% in the 3rd quarter. Sculati Wealth Management LLC now owns 2,047 shares of the biopharmaceutical company's stock worth $1,970,000 after acquiring an additional 38 shares in the last quarter. Finally, Pine Valley Investments Ltd Liability Co lifted its position in Regeneron Pharmaceuticals by 19.0% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 5,303 shares of the biopharmaceutical company's stock valued at $5,575,000 after acquiring an additional 848 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded up $15.61 on Friday, hitting $605.61. 1,606,415 shares of the company traded hands, compared to its average volume of 744,231. The business's 50 day moving average price is $626.49 and its 200-day moving average price is $711.45. Regeneron Pharmaceuticals, Inc. has a 52-week low of $525.99 and a 52-week high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $66.21 billion, a price-to-earnings ratio of 15.82, a P/E/G ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. During the same quarter last year, the firm posted $9.55 earnings per share. The company's revenue was down 3.7% compared to the same quarter last year. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.58%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.96%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on REGN. The Goldman Sachs Group lowered their target price on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a report on Wednesday. StockNews.com downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday. TD Cowen reduced their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a report on Tuesday, February 4th. Cantor Fitzgerald began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price target on the stock. Finally, Bernstein Bank reduced their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, eighteen have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $892.60.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.